Brimapitide: Risks & Legal Status

Critical Safety Information#

Brimapitide (AM-111) development has been discontinued. The drug will not proceed to regulatory approval. This information is provided for educational and historical reference only.

Risk Assessment#

Clinical Program Failure#

The brimapitide program ultimately failed for the following reasons:

• HEALOS Phase 3: Primary endpoint missed in the overall ISSNHL population
• ASSENT Phase 3: Terminated early (second confirmatory trial)
• Subgroup only: Efficacy signal limited to the profound hearing loss subgroup
• Post-hoc nature: The subgroup finding was identified after the trial, not pre-specified

Lessons from the Program#

The brimapitide story illustrates several important principles in drug development:

1. Target population selection: JNK activation may only be relevant in severe cochlear injury, meaning the drug was tested in too broad a population
2. Post-hoc vs. prospective: Subgroup findings require independent confirmation
3. Rare disease challenges: ISSNHL is difficult to study due to variable natural history and spontaneous recovery rates

Intratympanic Injection Risks#

While the drug itself showed a good safety profile, the administration procedure carries inherent risks:

Regulatory Status#

Brimapitide received FDA Fast Track designation in 2017, but this designation was rendered moot by the discontinuation of development.

Risk Assessment Context#

Brimapitide belongs to the Healing category of research peptides. Risk assessment for Brimapitide should consider both the compound-specific risks identified in clinical research and the broader regulatory environment. Researchers and healthcare providers should evaluate these risks in the context of the specific patient population and therapeutic indication.

Risk Categories#

The following risk categories have been identified for Brimapitide based on available evidence and regulatory assessments:

Discontinued Development#

Brimapitide development was discontinued in 2023 after the Phase 3 HEALOS trial failed to meet its primary endpoint and the ASSENT trial was terminated early. The drug is not being pursued for regulatory approval.

Failed Primary Endpoint#

The Phase 3 HEALOS trial did not demonstrate statistically significant efficacy in the overall ISSNHL population. The positive subgroup finding in profound hearing loss was a post-hoc analysis and was not prospectively confirmed.

Intratympanic Injection Risks#

The intratympanic injection procedure carries risks including tympanic membrane perforation, pain, vertigo, tinnitus, and rarely middle ear infection. These are procedure-related rather than drug- related risks.

Limited Efficacy Data#

The only positive efficacy signal was in a post-hoc subgroup of patients with profound hearing loss. Post-hoc analyses are hypothesis- generating and require prospective confirmation, which was not conducted.

Regulatory Status by Jurisdiction#

The regulatory and legal status of Brimapitide varies by country and jurisdiction. Researchers should verify current regulations before acquiring or using this compound.

Regulatory classifications can change. Researchers are responsible for complying with all applicable laws and regulations in their jurisdiction.

Important Warnings#

The following warnings apply to Brimapitide:

• Brimapitide development has been DISCONTINUED. It is not being developed for regulatory approval and will not become available as a treatment.
• The Phase 3 HEALOS trial FAILED to meet its primary endpoint. The positive subgroup finding in profound ISSNHL was a post-hoc analysis and has not been confirmed prospectively.
• Patients with sudden hearing loss should seek immediate medical attention and follow established treatment guidelines (oral corticosteroids, intratympanic steroids as salvage therapy).
• Research-grade D-JNKI-1 peptide is available from chemical suppliers but is intended for laboratory research only. Self-administration for hearing loss is dangerous and not supported by the clinical evidence.

These warnings are based on available preclinical and clinical data. The absence of a warning does not indicate safety. Consult qualified professionals before making any decisions regarding peptide research.

Related Reading#

• Brimapitide overview and research guide
• Brimapitide side effects profile
• Brimapitide research evidence